Clin Osteol 2013; 18(4): 137-142

Male osteoporosisReview articles

M. Skácelová, P. Horák

Male osteoporosis is a condition with an increasing incidence and relatively high mortality associated with fractures. A secondary etio­ logy is quite common, mostly contributed to by deficiency of sex hormones (testosterone, estradiol), other diseases and medication use. Prior to treatment initiation, a secondary etiology should be clearly ruled out. A significant role in the prevention and treatment is played by modification of lifestyle factors (physical activity, smoking, alcohol consumption, etc.) and sufficient calcium and vitamin D supplementation. In the treatment of male osteoporosis, bisphosphonates are currently used. If taken regularly, they increase BMD of the lumbar spine and proximal femur and aid in reducing the risk of osteoporotic fractures. Drugs currently approved for use are alen­ dronate, risedronate and zoledronic acid. Other drugs known to be effective in the treatment of male osteoporosis are strontium ranelate and teriparatide.

Keywords: osteoporosis, testosterone, bisphosphonates, strontium ranelate, teriparatide

Published: December 11, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skácelová M, Horák P. Male osteoporosis. Osteologický bulletin. 2013;18(4):137-142.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Center JR, Bliuc D, Nguyen TV et al. Risk of subsequent fra ma fracture in men and women. J Am Med Assoc 2007;297:387-394. Go to original source...
    2. Nguyen ND, Ahlborg HG, Center JR et al. Residual lifetime risk women and in men. J Bone Miner Res 2007;22:781-788. Go to original source...
    3. Jenšovský J. Osteoporóza u mužů. Interní Med 2013;15(1):15-18.
    4. Gennari L, Klein R, Ferrari S. in men; Elsevier 2010; pp.149-163. Go to original source...
    5. Ferrari SL, Deutsch S, Choudhury U et al. Polymorphism in the low-density lipo­ protein receptor-related protein 5 (LRP5) gene are associated with variation i tebral bone mass, vertebral bone size, and stature in whites. Am J Human Genet 2004;74:866-875. Go to original source...
    6. Li W-F, Hou S-X, Yu B et al. Genetic of osteoporosis: accelerating pace in identification and validation. Hum Genet 2010;127:249-285. Go to original source...
    7. Žofková I. Osteologie a kalcium - fosfátový metabolismus. Grada Publishing 2012; pp.11-23.
    8. Nordstrom P, Neovius M, Nordstrom A Early and rapid bone mineral of the proximal femur in men. J Clin Endocrinol Metab 2007;92:1902. Go to original source...
    9. Berger C, Langsetmo L, Joseph L et al. Change in bone mineral density as a fu tion of age in women and men and association with the use of antiresorptive agents. CMAJ 2008;178:1660. Go to original source...
    10. Orwoll E. Lambert LC Marshall LM et al. Group OFIMS. Testosterone and estra­ diol among older men. J Clin Endocrinol Metab 2006;91:1336-1344. Go to original source...
    11. Schuit SCE, Van der Klift M, Weel AE et al. Fracture incidence and associ with bone mineral density in elderly men and women: the Rotterdam study. Bone 2004;34:195-202. Go to original source...
    12. National Osteoporosis Foundation. Clinician's guide to prevention and tre of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2010.
    13. Hrdý P, Novosad P. Stroncium ranelát v léčbě osteoporózy u mužů. Farmakoterapie 2012; 8(6).
    14. McKenna MJ. Differences in vitamin D and the elderly. Am J Med 1992;93:69-77. Go to original source...
    15. Krexner E, Resch H, Pietschmann P et al. Vitamin D status in residents of a l term-care geriatric hospital in Vienna. Osteologie 1996;5:13-18.
    16. Chapuy MC, Durr F, Chapuy P. Age-related changes in parathyroid hormone and 25 hydroxycholecalciferol levels. J Gerontol 1996;38:19-22. Go to original source...
    17. Chapuy MC, Chapuy C, Meunier PJ. Calcium and vitamin D supplements: effects on calcium metabolism in elderly people. Am J Clin Nutr 1987;46:324-328. Go to original source...
    18. Chapuy MC, Arlot ME, DuBoef F et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-1642. Go to original source...
    19. Vieth R, Cole DE, Hawker GA et al. Wintertime vitamin D insufficiency is com­ mon in young Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 2001; 55:1091-1097. Go to original source...
    20. Välimäki VV, Alfthan H, Lehmusklallio E et al. Vitamin D status as a deter of peak bone mass in young finnish men. J Clin Endocrinol Metabol 2004;89: 76-80. Go to original source...
    21. Holick MF, Chen TC. Vitamin D deficiency: A world wide problem with health consequences. A J Clin Nutr 2008;87:1080-1086. Go to original source...
    22. Behre HM, Kliesch S, Leifke E et al. Long-term effect of testosterone therap bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82: 2386-2390. Go to original source...
    23. Amory JK, Watts NB, Easley KA et al. Exogenous testosterone or testosteronewith finasteride increases bone mineral density in older men with low serum tes­ tosterone. J Clin Endocrinol Metab 2004;89:503-510. Go to original source...
    24. Benito M, Vasilic B, Wehrli FW et al. Effect of testosterone replacement o becular architecture in hypogonadal men. J Bone Mineral Res 2005;20:1785-1791. Go to original source...
    25. Basaría S, Coviello AD, Travison TG et al. Adverse events associated with tes terone administration. N Engl J Med 2010;363:109-122. Go to original source...
    26. Sawka AM, Papaioannou A, Adachi JD et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005;6:39. Go to original source...
    27. Stoch SA, Saag KG, Greenwald M et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebocontrolled clinical trial. J Rheumatol 2009;36:1705-1714. Go to original source...
    28. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for pro­ state cancer: a randomized trial. Ann Intern Med 2007;146:416-424. Go to original source...
    29. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of estabilished p mary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004;24:110. Go to original source...
    30. Ringe JD, Faber H, Farahm and P, Dorst A Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006;26:427-431. Go to original source...
    31. Boonen S, Orwoll ES, Wenderoth D et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009;24:719-725. Go to original source...
    32. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-1809. Go to original source...
    33. Boonen S, Reginster JY, Kaufman JM et al. Fracture risk and zoledronic acid t rapy in men with osteoporosis. N Engl J Med 2012;367:1714-1723. Go to original source...
    34. Kaufman JM, Audran M, Bianchi G et al. Efficacy and safety of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int 2012;23(Suppl 2):S260. Go to original source...
    35. Ringe D, Dorst A, Farhamand P et al. Efficacy of strontium ranelate on bone neral density in men with osteoporosis. Arzneimittelfoschung 2010;60:267-272. Go to original source...
    36. Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving an­ drogen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-755. Go to original source...
    37. Orwoll ES, S cheele WH, Paul S et al. The effect of teriparatide [human p roid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.